The recruitment peak season is often referred to as the "Golden March, Silver April," and at the end of April, there is an even higher frequency of executive changes in the pharmaceuticals industry.
Johnson & Johnson China Chairman Song Weiqun Submitted Resignation; Johnson & Johnson Appoints HR Head for China Region; HuiRui Appoints Head of China Vaccines and Basic Business; Novartis to Replace Next Chairman of the Board.Zai Lab, Chief Commercial Officer Appointed;Multiple Personnel Changes at Shiyao Innovative Pharmaceuticals;Baili Tianheng's Wholly-Owned Subsidiary Appoints Chief Executive Officer.Johnson & Johnson China Chairman ResignsOn April 23, an internal email from Johnson & Johnson announced that Song Weiqun, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology China, has submitted his resignation to the company after careful consideration, seeking external development opportunities.In 2003, Song Weiqun joined Johnson & Johnson as a global management trainee; in 2006, he returned to China to serve as the head of the Ethicon China Division of Johnson & Johnson Medical Technology; in 2015, he was promoted to President of Johnson & Johnson Medical Technology in China; and from 2018 to present, he has concurrently served as the Chairman of Johnson & Johnson in China.Song Weiqun is a historic figure in the more than 130-year history of Johnson & Johnson.FirstChina Chairman grown locally;The first to propose positioning China as a "global innovation engine," making Johnson & JohnsonThe First OneA Fortune 500 company strategically deploying innovative positions in the Chinese market. Song Weiqun will continue to serve as the Chairman of Johnson & Johnson China and the President of Johnson & Johnson Medical Technology China until the end of September this year, overseeing all business operations and daily management to ensure a smooth transition and handover.Johnson & Johnson Appoints Human Resources Leader for China RegionJohnson & Johnson announced that Chen Yanli will assume the role of Human Resources Leader for Johnson & Johnson Medical Technology China & OneHR China, effective April 29. She will join the Johnson & Johnson Medical Technology China Board and the Asia-Pacific Human Resources Leadership Team.Data shows that Chen Yanli once served asDow ChemicalDirector of Human Resources, Asia-Pacific Region,LargeHR Director of Greater China, HR Business Partner for APAC Commercial and Business Development, and Head of APAC International Assignments. In 2019, Chen Yanli joined Roche as the Vice President of Talent and Organizational Culture at Roche Pharmaceuticals China. In 2022, her role expanded to also lead the Hospital Key Account Management Department for Market Access in China. On April 11 this year, Roche announced Chen Yanli's departure.Pfizer Appoints Head of China Vaccines and Essential BusinessAccording to a report by "Pharmaceutical Representative" on April 22, Pfizer has appointed Xiao Dong Jin as the head of Pfizer China's vaccine and essential business.GoldXiao Dong has extensive experience in the pharmaceutical industry,Solid experience and practical achievements in product commercialization strategy decisions, market and sales management, as well as team management. GoldXiao Dong曾就职于诺华、雅培、赛诺菲等公司。In June 2020, Xiao Dong Jin officially assumed the position of Chief Commercial Officer at InnoCare Pharma, leading teams in sales, marketing, market access, and distributor management to execute the company’s commercialization strategy.On February 20 this year, Jin Xiaodong transitioned to serve as the Chief Business Development Officer of InnoCare Pharma. Novartis' Next Chairman of the Board to Be ReplacedAccording to the latest foreign media reports, last November,Giovanni CaforioJoerg Reinhardt, who will succeed Novartis as the long-term chairman next year, plans to retire at the end of his 12-year term in December 2025.Giovanni Caforio worked at BMS for 20 years and was promoted to CEO of the company in 2015.During his eight-year tenure as CEO, Caforio oversaw several major acquisitions, the most notable of which was the $74 billion acquisition of Celgene, significantly expanding BMS's oncology drug business.Zai Lab, Chief Commercial Officer Appointed On April 22, the former Chief Operating Officer of Simcere Pharmaceutical,Simcere PharmaceuticalSenior Vice President Zhu Tong announced his joining Zai Lab as the Chief Commercial Officer of Greater China. The original Chief Commercial Officer and President of Greater China, Liang Yi, will leave Zai Lab.Destination Not Yet Disclosed。 Zhu Tong is a senior executive with both multinational and local pharmaceutical enterprise backgrounds.Previously held positions at top pharmaceutical companies such as Roche, Novartis, BMS, AstraZeneca, and Sanofi.Former Vice President of AstraZeneca China, Head of the Cardiovascular, Renal and Metabolic Diseases Division. Before joining Zai Lab, Zhu Tong served as the Senior Vice President at Simcere Pharmaceutical, where he was responsible for the marketing and management of innovative drugs in the hospital channel. He later served as the Chief Operating Officer at Ziming Simcere, a subsidiary, overseeing its nationwide marketing and pharmaceutical business in China.Multiple Personnel Changes at Shiyao Innovative Pharmaceuticals
On April 22, Shi YiXinuoleThe announcement of personnel changes mainly involves the company's directors, general manager, non-independent directors, and independent directors.Wang Huaiyu, Director of Shiyao Xinnuowei, Resigns and Will Not Hold Any Position in the Company After Resignation.Han Feng has applied to resign as General Manager, and Yao Bing will take over the position. Yao Bing is also a veteran of CSPC, having previously worked at CSPC Hebei Zhongrun Pharmaceutical Co., Ltd. and CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and has served as the Executive President of CSPC Pharmaceutical Group Limited.The Board nominated Dai Long and Xu Wen as non-independent director candidates for the Sixth Board of Directors, and nominated Mr. Zhou Jianping as an independent director candidate for the Sixth Board of Directors.Dai Long, born in June 1992, has previously worked at CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. He currently serves as the company's Chief Financial Officer, Board Secretary, and Securities Affairs Representative. He has also worked at Otsuka Pharmaceutical R&D (Beijing) Co., Ltd., CSPC Zhoqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Beijing Kangchuang United Biopharmaceutical Technology Research Co., Ltd., and CSPC Shanghai Yishi Pharmaceutical Technology Co., Ltd. He is now the Senior Director of the Securities Affairs Department at CSPC Group Co., Ltd.Baili Tianheng's Wholly-Owned Subsidiary Appoints Chief Executive OfficerOn April 23, Shanghai Belie Tianhe announced that its wholly-owned subsidiary, SystImmune, appointed Jie D'Elia as the company's new Chief Executive Officer today.D'Elia has over 20 years of experience in the biopharmaceutical industry and served as Senior Vice President at Bristol-Myers Squibb (BMS), overseeing business development in oncology, hematology, and cell therapy.D'Elia has extensive experience and a successful track record in the field of tumor immunotherapy. During his tenure at BMS, he led the development and commercialization of several key products, including Opdivo® (nivolumab) and Opdivo® in combination with Yervoy® (ipilimumab) for the treatment of melanoma, non-small cell lung cancer, renal cancer, andHead and Neck CancerHe also led the development of BMS's early oncology immunotherapy pipeline.SystImmune is a clinical-stage biotechnology company dedicated to developing novel cancer immunotherapies for the treatment of cancer. The company is currently developing multiple drug candidates targeting various cancer indications.Source: Pu Gongying Ouryao, Compiled by Wuyou
*This WeChat Official Account remains neutral on all original and reproduced content, statements, and viewpoint judgments. The shared content is for non-profit purposes only. If any reproduced works or images have incorrect author source markings or involve infringement, original authors are kindly reminded to contact the editor for removal.
*Editorial Responsibility| Mu Yang
*Reprint Authorization | Teacher Zhang 17551939537(WeChat same number))
*Business Cooperation | PartyTeacher13262726197(WeChat same number)
